David Aguilar

David Aguilar

Auto-generated profile, based on publicly available information

David Aguilar

Baylor College of Medicine, Houston, Texas

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2016 in Nature
Verified
Journal Article
Open access
PDF file
CFChristian Fuchsberger
Christian Fuchsberger
JFJason Flannick
Jason Flannick
TTTanya M. Teslovich
Tanya M. Teslovich
AMAnubha Mahajan
Anubha Mahajan
VAVineeta Agarwala
Vineeta Agarwala
MMMark I. McCarthy
Mark I. McCarthy
The genetic architecture of common traits, including the number, frequency, and effect sizes of inherited variants that contribute to individual risk, has been long debated. Genome-wide association studies have identified scores of common variants associated with type 2 diabetes, but in aggregate, these explain only a fraction of the heritability of this disease. Here, to test the hypothesis that lower-frequency variants explain much of the remainder, the GoT2D and T2D-GENES consortia performed whole-genome sequencing in 2,657 European individuals with and without diabetes, and exome sequencing in 12,940 individuals from five ancestry groups. To increase statistical power, we expanded the sample size via genotyping and imputation in a further 111,548 subjects. Variants associated with type 2 diabetes after sequencing were overwhelmingly common and most fell within regions previously identified by genome-wide association studies. Comprehensive enumeration of sequence variation is necessary to identify functional alleles that provide important clues to disease pathophysiology, but large-scale sequencing does not support the idea that lower-frequency variants have a major role in predisposition to type 2 diabetes.

1 March 2012 in JACC
Verified
Journal Article
Closed access
SASameer Ather
Sameer Ather
WCWenyaw Chan
Wenyaw Chan
BBBiykem Bozkurt
Biykem Bozkurt
DADavid Aguilar
David Aguilar
KRKumudha Ramasubbu
Kumudha Ramasubbu
ADAnita Deswal
Anita Deswal

13 August 2019 in Circulation
Verified
Journal Article
Closed access
PDF file
SDShannon M. Dunlay
Shannon M. Dunlay
MGMichael M. Givertz
Michael M. Givertz
DADavid Aguilar
David Aguilar
LALarry A. Allen
Larry A. Allen
MCMichael Chan
Michael Chan
TAThe Heart Failure Society Of America
The Heart Failure Society Of America
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.

6 December 2016 in Circulation
Verified
Journal Article
Open access
PDF file
BBBiykem Bozkurt
Biykem Bozkurt
DADavid Aguilar
David Aguilar
ADAnita Deswal
Anita Deswal
SDSandra B. Dunbar
Sandra B. Dunbar
GFGary S. Francis
Gary S. Francis
CYClyde Yancy
Clyde Yancy
He comorbidities of hypertension, diabetes mellitus, obesity, hyperlipidemia, and metabolic syndrome are common in patients with heart failure (HF) and affect clinical outcomes. 1-3 Interestingly, although these comorbidities are associated with the development of incident HF in the general population, in patients with established HF, their contributory roles to clinical outcomes are not predictable, and their management is quite challenging. Recent American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) guidelines have addressed the role of lifestyle modification, 4 treatment of blood cholesterol, 5 and management of overweight and obesity 6 in the general population and in patients with increased cardiovascular risk, and a recent report from the Eighth Joint National Committee addressed the management of hypertension. 7 However, these guidelines did not specifically address the management of such comorbidities in patients with HF. Similarly, the most recent ACCF/AHA HF practice guidelines 8 in 2013 addressed the overall management of comorbidities in patients with HF in broad terms, but again, specific and detailed recommendations on how to manage hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome are lacking. The intent of this AHA scientific statement is to summarize data relevant to contributory risk and to provide guidance on the management of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in the development and prognosis of HF to provide recommendations (Table 1) and to foster communication between physicians and other healthcare professionals and patients on the management of these comorbidities. Recommendations in this document are based on published studies and the multidisciplinary expertise of the writing group and harmonized with published practice guidelines from the ACC/AHA 4-6,8-12 and other organizations. 7,13-15

18 December 2013 in JAMA
Verified
Journal Article
Open access
PDF file
HCHorng H. Chen
Horng H. Chen
KAKevin J. Anstrom
Kevin J. Anstrom
MGMichael M. Givertz
Michael M. Givertz
LSLynne W. Stevenson
Lynne W. Stevenson
MSMarc J. Semigran
Marc J. Semigran
FNfor the NHLBI Heart Failure Clinical Research Network
for the NHLBI Heart Failure Clinical Research Network
A primary treatment goal in acute heart failure is to achieve adequate decongestion while avoiding renal dysfunction and other adverse effects.1,2 Patients with acute heart failure and moderate or severe renal dysfunction are at risk for inadequate decongestion and worsening renal function, both of which are associated with worse outcomes.3 Renal adjuvant therapies that enhance decongestion and preserve renal function during treatment of acute heart failure are needed.2,4

25 April 2012 in JAMA
Verified
Journal Article
Closed access
EPEmerson C. Perin
Emerson C. Perin
JWJames T. Willerson
James T. Willerson
CPCarl J. Pepine
Carl J. Pepine
THTimothy D. Henry
Timothy D. Henry
SEStephen G. Ellis
Stephen G. Ellis
RSRobert D. Simari
Robert D. Simari
Previous studies using autologous bone marrow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy have demonstrated safety and suggested efficacy. To determine if administration of BMCs through transendocardial injections improves myocardial perfusion, reduces left ventricular end-systolic volume (LVESV), or enhances maximal oxygen consumption in patients with coronary artery disease or LV dysfunction, and limiting heart failure or angina. A phase 2 randomized double-blind, placebo-controlled trial of symptomatic patients (New York Heart Association classification II-III or Canadian Cardiovascular Society classification II-IV) with a left ventricular ejection fraction of 45% or less, a perfusion defect by single-photon emission tomography (SPECT), and coronary artery disease not amenable to revascularization who were receiving maximal medical therapy at 5 National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network (CCTRN) sites between April 29, 2009, and April 18, 2011. Bone marrow aspiration (isolation of BMCs using a standardized automated system performed locally) and transendocardial injection of 100 million BMCs or placebo (ratio of 2 for BMC group to 1 for placebo group). Co-primary end points assessed at 6 months: changes in LVESV assessed by echocardiography, maximal oxygen consumption, and reversibility on SPECT. Phenotypic and functional analyses of the cell product were performed by the CCTRN biorepository core laboratory. Of 153 patients who provided consent, a total of 92 (82 men; average age: 63 years) were randomized (n = 61 in BMC group and n = 31 in placebo group). Changes in LVESV index (-0.9 mL/m(2) [95% CI, -6.1 to 4.3]; P = .73), maximal oxygen consumption (1.0 [95% CI, -0.42 to 2.34]; P = .17), and reversible defect (-1.2 [95% CI, -12.50 to 10.12]; P = .84) were not statistically significant. There were no differences found in any of the secondary outcomes, including percent myocardial defect, total defect size, fixed defect size, regional wall motion, and clinical improvement. Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT. clinicaltrials.gov Identifier: NCT00824005.